Literature DB >> 25498902

Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.

Charlotte E Johnson1, David K Hunt1, Marie Wiltshire1, Terry P Herbert2, Julian R Sampson1, Rachel J Errington1, D Mark Davies1, Andrew R Tee3.   

Abstract

Inappropriate activation of mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is common in cancer and has many cellular consequences including elevated endoplasmic reticulum (ER) stress. Cells employ autophagy as a critical compensatory survival mechanism during ER stress. This study utilised drug-induced ER stress through nelfinavir in order to examine ER stress tolerance in cell lines with hyper-active mTORC1 signalling. Our initial findings in wild type cells showed nelfinavir inhibited mTORC1 signalling and upregulated autophagy, as determined by decreased rpS6 and S6K1 phosphorylation, and SQTSM1 protein expression, respectively. Contrastingly, cells with hyper-active mTORC1 displayed basally elevated levels of ER stress which was greatly exaggerated following nelfinavir treatment, seen through increased CHOP mRNA and XBP1 splicing. To further enhance the effects of nelfinavir, we introduced chloroquine as an autophagy inhibitor. Combination of nelfinavir and chloroquine significantly increased ER stress and caused selective cell death in multiple cell line models with hyper-active mTORC1, whilst control cells with normalised mTORC1 signalling tolerated treatment. By comparing chloroquine to other autophagy inhibitors, we uncovered that selective toxicity invoked by chloroquine was independent of autophagy inhibition yet entrapment of chloroquine to acidified lysosomal/endosomal compartments was necessary for cytotoxicity. Our research demonstrates that combination of nelfinavir and chloroquine has therapeutic potential for treatment of mTORC1-driven tumours.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; Cancer; Chloroquine; ER stress; Nelfinavir; TSC; mTOR

Mesh:

Substances:

Year:  2014        PMID: 25498902      PMCID: PMC5528710          DOI: 10.1016/j.molonc.2014.11.005

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  55 in total

1.  Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.

Authors:  Simmy Thomas; Natasha Sharma; Encouse B Golden; Heeyeon Cho; Puneet Agarwal; Kevin J Gaffney; Nicos A Petasis; Thomas C Chen; Florence M Hofman; Stan G Louie; Axel H Schönthal
Journal:  Cancer Lett       Date:  2012-06-01       Impact factor: 8.679

2.  The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Authors:  Camille Bono; Lionel Karlin; Stephanie Harel; Enguerran Mouly; Sylvaine Labaume; Lionel Galicier; Sébastien Apcher; Hélène Sauvageon; Jean-Paul Fermand; Jean-Christophe Bories; Bertrand Arnulf
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 3.  Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium.

Authors:  M Høyer-Hansen; M Jäättelä
Journal:  Cell Death Differ       Date:  2007-07-06       Impact factor: 15.828

4.  Gadd34 induces autophagy through the suppression of the mTOR pathway during starvation.

Authors:  Mohammad Nizam Uddin; Sachiko Ito; Naomi Nishio; Thanasegaran Suganya; Ken-ichi Isobe
Journal:  Biochem Biophys Res Commun       Date:  2011-03-23       Impact factor: 3.575

Review 5.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

6.  Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.

Authors:  Emilia Mahoney; Kami Maddocks; Joseph Flynn; Jeffrey Jones; Sara L Cole; Xiaoli Zhang; John C Byrd; Amy J Johnson
Journal:  Leuk Lymphoma       Date:  2013-04-16

7.  Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer.

Authors:  Jeroen Buijsen; Guido Lammering; Rob L H Jansen; Geerard L Beets; Jaap Wals; Meindert Sosef; Marien O Den Boer; Jeroen Leijtens; Robert G Riedl; Jan Theys; Philippe Lambin
Journal:  Radiother Oncol       Date:  2013-05-03       Impact factor: 6.280

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding.

Authors:  Elaine A Dunlop; David K Hunt; Hugo A Acosta-Jaquez; Diane C Fingar; Andrew R Tee
Journal:  Autophagy       Date:  2011-07-01       Impact factor: 16.016

10.  Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest.

Authors:  Ian G Ganley; Pui-Mun Wong; Noor Gammoh; Xuejun Jiang
Journal:  Mol Cell       Date:  2011-06-24       Impact factor: 17.970

View more
  15 in total

1.  ER stress: Autophagy induction, inhibition and selection.

Authors:  Harun-Or Rashid; Raj Kumar Yadav; Hyung-Ryong Kim; Han-Jung Chae
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

2.  Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors.

Authors:  Jaclyn Lopiccolo; Shigeru Kawabata; Joell J Gills; Phillip A Dennis
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.

Authors:  Lei Zhang; Maria B Hapon; Alicia A Goyeneche; Rekha Srinivasan; Carlos D Gamarra-Luques; Eduardo A Callegari; Donis D Drappeau; Erin J Terpstra; Bo Pan; Jennifer R Knapp; Jeremy Chien; Xuejun Wang; Kathleen M Eyster; Carlos M Telleria
Journal:  Mol Oncol       Date:  2016-05-17       Impact factor: 6.603

4.  Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.

Authors:  Charlotte E Johnson; Elaine A Dunlop; Sara Seifan; Henry D McCann; Trevor Hay; Geraint J Parfitt; Ashley T Jones; Peter J Giles; Ming H Shen; Julian R Sampson; Rachel J Errington; D Mark Davies; Andrew R Tee
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

5.  Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.

Authors:  Elaine A Dunlop; Charlotte E Johnson; Marie Wiltshire; Rachel J Errington; Andrew R Tee
Journal:  Oncotarget       Date:  2017-07-25

6.  The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo.

Authors:  Steffi Liebscher; Lydia Koi; Steffen Löck; Michael H Muders; Mechthild Krause
Journal:  Clin Transl Radiat Oncol       Date:  2017-01-05

7.  The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.

Authors:  Vanessa Meier-Stephenson; Justin Riemer; Aru Narendran
Journal:  Onco Targets Ther       Date:  2017-05-16       Impact factor: 4.147

Review 8.  Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.

Authors:  Okio Hino; Toshiyuki Kobayashi
Journal:  Cancer Sci       Date:  2017-01-23       Impact factor: 6.716

9.  Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.

Authors:  Charlotte E Johnson; David K Hunt; Marie Wiltshire; Terry P Herbert; Julian R Sampson; Rachel J Errington; D Mark Davies; Andrew R Tee
Journal:  Mol Oncol       Date:  2014-11-22       Impact factor: 6.603

10.  Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings.

Authors:  Mitzie-Ann Davis; Joe R Delaney; Chandni B Patel; Ryan Storgard; Dwayne G Stupack
Journal:  Drug Des Devel Ther       Date:  2016-06-02       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.